Strategic asset sale Seelos Therapeutics recently completed asset sales to GLD Partners, signaling potential liquidity events and a need for transitional partnerships or licensing discussions for remaining assets.

BD leadership shift Appointment of a new Chairman of the Board to lead business development discussions indicates a focused mandate on strategic partnerships and potential collaborations to maximize value.

Public market activity Recent public offering activity and ongoing exposure on Nasdaq suggest heightened investor scrutiny and opportunities for partnership or co development deals that align with fundraising needs.

CNS and rare disease focus Portfolio emphasis on CNS disorders and orphan diseases positions the company for collaboration with specialty biotech firms, academic partnerships, and grant-funded programs seeking novel therapies.

Financial posture Funding of approximately $66 million and sub-$1 million revenue imply a need for non-dilutive partnerships, licensing opportunities, or milestone-driven deals to sustain development pipelines.